Publication Name	World Journal of Clinical Oncology
Manuscript ID	102735
Country	China

Received	2024-10-28 09:32
Peer-Review Started	2024-10-28 09:32
To Make the First Decision
Return for Revision	2024-12-05 10:16
Revised	2024-12-16 10:38
Second Decision	2025-01-23 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-01-23 09:25
Articles in Press	2025-01-23 09:25
Publication Fee Transferred	2024-12-19 05:25
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-02-18 06:42
Publish the Manuscript Online	2025-03-26 10:16

ISSN	2218-4333 (online)
Open Access	Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Xu Zhang, Xu Zhang, Qian-Kun Luo, Qiang Fu, Pan Liu, Chang-Jie Pan, Chuan-Jiang Liu, Hong-Wei Zhang and Tao Qin
ORCID	Author(s) ORCID Number Xu Zhang http://orcid.org/0000-0001-6553-1214 Xu Zhang http://orcid.org/0009-0004-9939-6398 Qian-Kun Luo http://orcid.org/0000-0002-2997-5026 Qiang Fu http://orcid.org/0000-0002-9457-2434 Pan Liu http://orcid.org/0000-0002-6600-5432 Chang-Jie Pan http://orcid.org/0009-0003-3775-8915 Chuan-Jiang Liu http://orcid.org/0000-0001-6766-554X Hong-Wei Zhang http://orcid.org/0000-0002-3848-9222 Tao Qin http://orcid.org/0000-0002-1303-9217
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Henan Province 242300421286 The research and practice project of higher education reform in Henan Province 2023SJGLX124Y The research and practice project of higher education reform of ZhengZhou University 2023ZZUJGXM114
Corresponding Author	Tao Qin, PhD, Professor, Department of Hepato-Biliary-Pancreatic Surgery, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. goodfreecn@163.com
Key Words	Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; Hepatocellular carcinoma; Targeted combination immunotherapy; Relative hepatobiliary enhancement ratio; Effect prediction
Core Tip	In recent years, molecular-targeted drugs combined with immunotherapy and other therapeutic methods have provided new treatment options for mid-to-advanced hepatocellular carcinoma, and predicting the effect of targeted combined immunotherapy has become a hot topic in current research. The degree of enhancement of advanced hepatocellular carcinoma nodules in the hepatobiliary stage on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging was significantly correlated with progression-free survival. The imaging information of nodules in the hepatobiliary stage and clinical immunological indicators have high predictive efficacy for targeted combined immunotherapy and are associated with progression-free survival in patients.
Publish Date	2025-03-26 10:16
Citation	<p>Zhang X, Zhang X, Luo QK, Fu Q, Liu P, Pan CJ, Liu CJ, Zhang HW, Qin T. Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma. <i>World J Clin Oncol</i> 2025; 16(4): 102735</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i4/102735.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i4.102735

Full Article (PDF)	WJCO-16-102735-with-cover.pdf
Manuscript File	102735_Auto_Edited_060130.docx
Answering Reviewers	102735-answering-reviewers.pdf
Audio Core Tip	102735-audio.mp3
Biostatistics Review Certificate	102735-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	102735-conflict-of-interest-statement.pdf
Copyright License Agreement	102735-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	102735-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	102735-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	102735-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	102735-non-native-speakers.pdf
Peer-review Report	102735-peer-reviews.pdf
Scientific Misconduct Check	102735-scientific-misconduct-check.png
Scientific Editor Work List	102735-scientific-editor-work-list.pdf
CrossCheck Report	102735-crosscheck-report.pdf